Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220973 · ClinicalTrials.gov registry record · Phase 2
Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01220973 is a Phase 2 study that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 27 participants.
The verdict
NCT01220973, a Phase 2 study, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
RATIONALE: Atorvastatin calcium and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atorvastatin calcium together with celecoxib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving atorvastatin calcium together with celecoxib works in treating patients with rising PSA levels after local therapy for prostate cancer.
Interventions
- OTHER laboratory biomarker analysis
- DRUG celecoxib
- DRUG atorvastatin calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-02 |
| Est. Completion | 2014-11-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220973
The ClinicalTrials.gov registry entry for NCT01220973 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01220973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01220973 about?
NCT01220973 is a clinical study titled "Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer". RATIONALE: Atorvastatin calcium and celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atorvastatin calcium together with celecoxib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving atorvastatin calcium toget...
What is the current status of trial NCT01220973?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2009-02. Estimated completion is 2014-11-18.
What interventions are being tested in trial NCT01220973?
The interventions under investigation include: laboratory biomarker analysis (OTHER), celecoxib (DRUG), atorvastatin calcium (DRUG).
Who is sponsoring clinical trial NCT01220973?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.